JOP20180029A1 - مركب حلقي غير متجانس - Google Patents

مركب حلقي غير متجانس

Info

Publication number
JOP20180029A1
JOP20180029A1 JOP/2018/0029A JOP20180029A JOP20180029A1 JO P20180029 A1 JOP20180029 A1 JO P20180029A1 JO P20180029 A JOP20180029 A JO P20180029A JO P20180029 A1 JOP20180029 A1 JO P20180029A1
Authority
JO
Jordan
Prior art keywords
heterocyclic compound
ip6k
preventive
diabetes
diseases
Prior art date
Application number
JOP/2018/0029A
Other languages
Arabic (ar)
English (en)
Inventor
Terao Yoshito
Yamasaki Takeshi
Hara Ryoma
Kasai Shizuo
Hidaka Kousuke
Takahashi Masashi
Furukawa Hideki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62134158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20180029(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of JOP20180029A1 publication Critical patent/JOP20180029A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JOP/2018/0029A 2017-03-30 2018-03-29 مركب حلقي غير متجانس JOP20180029A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017066579 2017-03-30

Publications (1)

Publication Number Publication Date
JOP20180029A1 true JOP20180029A1 (ar) 2019-01-30

Family

ID=62134158

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0029A JOP20180029A1 (ar) 2017-03-30 2018-03-29 مركب حلقي غير متجانس

Country Status (23)

Country Link
US (1) US10968178B2 (cg-RX-API-DMAC7.html)
EP (1) EP3601256A1 (cg-RX-API-DMAC7.html)
JP (1) JP7063915B2 (cg-RX-API-DMAC7.html)
KR (1) KR102597117B1 (cg-RX-API-DMAC7.html)
CN (1) CN110461828B (cg-RX-API-DMAC7.html)
AR (1) AR111307A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018246053B2 (cg-RX-API-DMAC7.html)
CA (1) CA3057821A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019002662A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012125A2 (cg-RX-API-DMAC7.html)
EA (1) EA038177B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19077969A (cg-RX-API-DMAC7.html)
IL (1) IL269347B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20180029A1 (cg-RX-API-DMAC7.html)
MA (1) MA49006A (cg-RX-API-DMAC7.html)
MX (1) MX393896B (cg-RX-API-DMAC7.html)
PE (1) PE20191656A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502248A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201908894SA (cg-RX-API-DMAC7.html)
TW (1) TWI778038B (cg-RX-API-DMAC7.html)
UA (1) UA125445C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018182051A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201907136B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389798B (es) 2017-01-20 2025-03-20 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
JP7690493B2 (ja) * 2020-05-04 2025-06-10 大鵬薬品工業株式会社 Iapアンタゴニスト化合物及びその中間体、並びにそれを合成する方法
UY39609A (es) * 2021-01-12 2022-08-31 Servier Lab Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
CA3250650A1 (en) * 2022-02-11 2023-08-17 The University Of North Carolina At Chapel Hill ARYLBENZOISOXAZOLE COMPOUNDS USED AS IP6K AND IPMK INHIBITORS AND THEIR METHODS OF USE
US20250346572A1 (en) * 2022-06-16 2025-11-13 Lieber Institute, Inc. Non-acid inhibitors of inositol hexakisphosphate kinase (ip6k) and methods of use thereof
CN115747325A (zh) * 2022-11-10 2023-03-07 上海交通大学医学院附属新华医院 Ip6k1及其产物作为增加血液脂联素药物靶点的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US7045527B2 (en) * 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Mcl−1タンパク質を阻害する化合物
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.

Also Published As

Publication number Publication date
SG11201908894SA (en) 2019-10-30
KR102597117B1 (ko) 2023-11-01
AU2018246053A1 (en) 2019-11-14
IL269347B2 (en) 2023-04-01
WO2018182051A8 (en) 2019-04-11
AU2018246053B2 (en) 2022-02-17
ECSP19077969A (es) 2020-02-28
EA201992306A1 (ru) 2020-02-20
TWI778038B (zh) 2022-09-21
AR111307A1 (es) 2019-06-26
JP2020515620A (ja) 2020-05-28
CA3057821A1 (en) 2018-10-04
JP7063915B2 (ja) 2022-05-09
CN110461828B (zh) 2022-07-19
BR112019020194A2 (pt) 2020-04-22
CL2019002662A1 (es) 2020-01-24
PE20191656A1 (es) 2019-11-07
CN110461828A (zh) 2019-11-15
NZ758061A (en) 2026-02-27
US10968178B2 (en) 2021-04-06
US20200377458A1 (en) 2020-12-03
AU2018246053A8 (en) 2019-11-21
UA125445C2 (uk) 2022-03-09
CO2019012125A2 (es) 2020-01-17
MX393896B (es) 2025-03-19
TW201840534A (zh) 2018-11-16
PH12019502248A1 (en) 2020-06-29
KR20190134676A (ko) 2019-12-04
IL269347A (en) 2019-11-28
WO2018182051A1 (en) 2018-10-04
IL269347B (en) 2022-12-01
EA038177B1 (ru) 2021-07-20
MX2019011783A (es) 2020-02-10
MA49006A (fr) 2020-02-05
ZA201907136B (en) 2021-07-28
EP3601256A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
MX393896B (es) Inhibidores de ip6k.
GEAP202215378A (en) Microbiocidal thiazole derivatives
EA201990833A1 (ru) Соединение пиридина
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
SG11201901061QA (en) Heterocyclic compound
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
EA201591743A1 (ru) СТИМУЛЯТОРЫ sGC
MX394082B (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim.
EA201201648A1 (ru) Стимуляторы sgc
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
MX2015015168A (es) Derivados heterociclicos y sus usos.
JOP20210039B1 (ar) مركبات بيريدين 6،2 - ديامينو
SG11201805791RA (en) COMPOSITION FOR INCREASING EXPRESSION OF PGC-1α
EA201790912A1 (ru) Гетероциклическое соединение
PH12017502221A1 (en) Use of benzimidazole derivatives for nocturnal acid breakthrough
EA201692270A1 (ru) Производные нафтиридиндиона
NZ711191A (en) Benzo-fused heterocyclic derivatives useful as agonists of gpr120
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
MX2021003481A (es) Compuesto heterociclico.
CR20170261A (es) Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa
MX390752B (es) Compuesto heterociclico.
MX381332B (es) Derivados novedosos de pirrolidina.
MX392946B (es) Compuesto heterociclico.